Canadian biotechnology company VoxCell BioInnovation and life sciences organisation adMare BioInnovations have entered into a research partnership aimed at validating the scientific and commercial potential of a novel antibody-based immune-modulating therapy using advanced human-relevant vascularised cancer tissue models.

The collaboration will leverage VoxCell’s 3D bioprinted tissue platform, which combines human tumour, immune and stromal components with perfusable endothelial-lined vasculature in a single construct. The platform is designed to replicate antibody delivery, immune interactions and tumour biology more accurately than traditional in vitro and animal models, offering quantitative insights into both efficacy and safety outcomes.

The partnership comes at a time when the US Food and Drug Administration (FDA) is encouraging the use of New Approach Methodologies (NAMs), including organ-on-chip systems, AI-based tools and human-relevant 3D tissue models, to reduce dependence on animal testing and improve the predictive accuracy of preclinical studies for monoclonal antibodies and biologics.

Matthew J. Carlyle, President and CEO of adMare BioInnovations, said the collaboration aligns with adMare’s goal of translating scientific discoveries into commercially viable Canadian life sciences companies. He noted that integrating VoxCell’s vascularised tissue technology into the validation process could help generate stronger preclinical safety and efficacy data at an earlier stage, reducing development risk and supporting the creation of globally competitive biotech ventures.

VoxCell’s platform is based on high-resolution bioprinting technology capable of producing perfusable vascular networks inside immune-competent human-like tissues. The technology is particularly suited for evaluating large biologics and immune-modulating therapies where antibody transport, endothelial barrier function and immune complexity are critical to therapeutic performance.

Dr. Karolina Valente, CEO and Chief Scientific Officer of VoxCell, said the company’s vascularised tissue models are designed to capture biological mechanisms often missed by animal testing. According to her, the collaboration demonstrates the growing relevance of human-relevant testing platforms in improving drug development decisions while reducing animal usage.

The data generated through the collaboration will contribute to adMare’s programme development efforts and support broader initiatives to establish VoxCell’s vascularised cancer tissue model as a recognised reference platform for immuno-oncology biologics.

VoxCell BioInnovation develops physiologically relevant human-like tissue models aimed at accelerating drug development through improved preclinical testing. adMare BioInnovations focuses on building and scaling Canadian life sciences companies through early-stage investment, scientific expertise, commercial R&D support and infrastructure development.